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function
Prema Narayan*
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The luteinizing hormone/chorionic gonadotropin receptor (LHCGR) is essential for fertility 
in men and women. LHCGR binds luteinizing hormone (LH) as well as the highly homol-
ogous chorionic gonadotropin. Signaling from LHCGR is required for steroidogenesis 
and gametogenesis in males and females and for sexual differentiation in the male. 
The importance of LHCGR in reproductive physiology is underscored by the large num-
ber of naturally occurring inactivating and activating mutations in the receptor that result 
in reproductive disorders. Consequently, several genetically modified mouse models 
have been developed for the study of LHCGR function. They include targeted deletion of 
LH and LHCGR that mimic inactivating mutations in hormone and receptor, expression 
of a constitutively active mutant in LHCGR that mimics activating mutations associated 
with familial male-limited precocious puberty and transgenic models of LH and hCG 
overexpression. This review summarizes the salient findings from these models and their 
utility in understanding the physiological and pathological consequences of loss and gain 
of function in LHCGR signaling.
Keywords: luteinizing hormone receptor, gonadotropins, inactivating and activating mutations, genetic models, 
knockout mice, knockin mice, transgenic mice
introduction
The luteinizing hormone/chorionic gonadotropin receptor (LHCGR), together with the glyco-
protein hormone receptors, follicle-stimulating hormone receptor (FSHR) and thyroid stimulating 
hormone receptor (TSHR), belongs to the G protein-coupled receptor superfamily (1). LHCGR is 
the target receptor for the pituitary-derived luteinizing hormone (LH) and the highly homologous 
placental chorionic gonadotropin (CG). The fully processed human LHCGR is 675 amino acid resi-
dues long and is characterized by a large extracellular domain that is sufficient for hormone binding 
(2). The LHCGR has 11 exons with the first 10 exons encoding the extracellular domain and exon 
11 encoding the C-terminal tail of the hinge region of the extracellular domain, the transmembrane 
helices with the connecting extra- and intracellular loops, and the cytoplasmic tail (1, 2). Functional 
LHCGR is essential for sex differentiation in the fetus and reproductive function in the adult. During 
fetal development in males, LHCGR present in the interstitial fetal Leydig cells of the testis binds to 
placental CG to produce testosterone required for male sexual differentiation (3, 4). Postnatally, LH 
stimulates LHCGR in the Leydig cells to produce testosterone required for development of puberty, 
male secondary sexual characteristics, and spermatogenesis. Female fetal sex differentiation does not 
require LH or steroid hormones. Postnatally, in females, LHCGR is present in the theca cells lining 
the follicle, mature granulosa cells, stromal cells, and luteinized cells. LH activation of LHCGR in the 
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theca cells stimulates androgen production, thereby providing 
the substrate for conversion to estradiol by follicle-stimulating 
hormone (FSH) induced aromatase in granulosa cells and trig-
gering puberty (5). LHCGR activation is required for ovulation 
and subsequent progesterone production by the corpus luteum 
(6). The canonical signaling pathway mediated by LHCGR for 
steroidogenesis is the Gαs/cAMP/protein kinase A pathway. 
However, LHCGR can also activate additional pathways, includ-
ing the Gαq/inositol phosphate/protein kinase C, protein kinase 
B, and ERK1/2 pathways (6–10). In the testis, the ERK1/2 cascade 
modulates androgen synthesis as well as proliferation/survival 
of Leydig cells (11–15). In the ovary, LHCGR-mediated activa-
tion of the EGF network and ERK1/2 cascade via Gαs/cAMP 
is required for resumption of meiosis, cumulus expansion, and 
luteinization, whereas follicular rupture is dependent on both 
Gαs and Gαq/11 (6, 16).
Naturally Occurring Mutations in LHCGR 
and LHB Genes
The large number of naturally occurring mutations and poly-
morphisms in the LHCGR gene that result in disorders of sexual 
development and reproductive function (4, 17) highlights the 
critical role of this receptor in reproduction. Mutations are 
inactivating, resulting in loss of receptor function, or activating 
resulting in constitutive activation of the receptor. These muta-
tions have been particularly useful in elucidating the molecular 
mechanisms of LHCGR activation. Inactivating mutations are 
present in all domains of the receptor and may be missense muta-
tions, insertions, deletions, and nonsense mutations. As a result, 
there may be partial inactivation or complete loss of receptor 
function caused by premature truncation of the receptor protein 
or failure to traffic to the cell surface (18). The mutations are 
recessive (19) and patients are either homozygous or compound 
heterozygous carriers. In males, inactivating mutations result in 
failure of testicular Leydig cell differentiation, resulting in the 
disorder called Leydig cell hypoplasia (LCH). Two types of Leydig 
cell hypoplasia are identified. The severe form is caused by muta-
tions that result in loss of receptor protein, failure of receptor to 
traffic to cell surface, or failure to transduce a signal. This results 
in 46,XY male pseudohermaphroditism with female external 
genitalia, undescended testes, low testosterone, and high LH 
levels. The milder form, caused by mutations that allow partial 
LHR function, results in micropenis and hypospadia (4, 17, 20). 
Testicular histology showed hyalinized basement membrane in 
the seminiferous tubules with Sertoli cells but few or no germ cells 
(4). Females with inactivating mutations exhibit amenorrhea and 
infertility, but normal feminization at puberty indicating that LH 
is not essential for pubertal development. Activating mutations 
resulting in single amino acid replacements in LHCGR were the 
first to be described in patients with familial male-limited preco-
cious puberty (FMPP) (21, 22). This is a rare disorder affecting 
upto 9/million (Orphanet/NIH, Office of Rare Diseases). In 
early studies, before the availability of molecular analyses, this 
disorder was called familial testotoxicosis (23, 24). These muta-
tions are heterozygous and inherited in an autosomal dominant 
male-limited pattern although a few sporadic cases have been 
reported (25). Clinically, these boys present with precocious 
puberty by 3–4  years of age, Leydig cell hyperplasia, and high 
circulating levels of testosterone in the context of prepubertal 
levels of LH (26–28). Surprisingly, female carriers of activating 
mutations are normal. The mutations are limited to exon 11 and 
clustered in transmembrane helix 6 and the third intracellular 
loop with aspartic acid at position 578 most commonly mutated 
to glycine (D578G) (22, 28). This mutation is found in about 62% 
of all FMPP cases and 29% of all sporadic cases of male-limited 
precocious puberty (29). Only one activating somatic mutation 
(D578H) has been identified so far in boys with precocious 
puberty and Leydig cell adenomas (30–32) and this mutation has 
not been identified in boys with FMPP.
In contrast to the large number of activating and inactivating 
mutations in LHCGR, no germ line mutations in the common 
α-subunit or hCGβ subunits and no gain-of-function mutations 
in LHβ have been identified. Only three inactivating mutations in 
LHβ resulting in complete loss of bioactive LH have been reported 
in four men and one woman (33–35). In all cases, the males were 
normally masculinized at birth but later presented with delayed 
or lack of spontaneous puberty, hypogonadism, low testosterone 
levels, and infertility. Testicular biopsy revealed absence of com-
plete spermatogenesis and mature Leydig cells (33, 34). This sug-
gests that LH is not required for male sexual differentiation. Fetal 
testosterone production begins autonomously and then becomes 
dependent on maternal hCG activation of LHCGR. Postnatal 
testicular development and function is, however, dependent on 
pituitary LH. Treatment with exogenous LH and hCG resulted in 
an increase in testosterone, indicating that receptor function was 
normal (33). The single female patient showed normal pubertal 
development but presented with secondary amenorrhea and 
infertility (35). The normal pubertal development is similar to 
that seen in women with a homozygous inactivating mutation 
in the LHCGR gene (36–39). A fourth mutation resulting in a 
deletion of amino acid residues 10–12 of LHβ was reported in 
a man and his sister (40). In spite of undetectable levels of LH 
and low serum and intratesticular testosterone, the man had 
complete spermatogenesis and normal sperm count. The low 
residual activity of the mutant LH detected in vitro was apparently 
sufficient for normal spermatogenesis. The single female patient 
underwent normal puberty, but developed secondary amenor-
rhea and infertility (35).
Genetic Models to Study LHCGR Function
Several mouse models have been developed that model human 
reproductive disorders involving LHCGR signaling. They include 
knockout models of LH and LHCGR to mimic the inactivating 
LHβ and LHCGR mutations (41–43) and knockin mice express-
ing a constitutively active mutant LHCGR (44, 45) to mimic the 
activating LHCGR mutations. In addition, several transgenic 
models of enhanced LH/hCG action have been generated. They 
include mice expressing the LHβ-CGβ carboxyl terminal peptide 
(CTP) fusion protein under the control of the bovine common α 
subunit promoter (46), mice expressing hCG under the control 
of the ubiquitin C (47, 48) or metallothionein promoter (49), 
and mice expressing a yoked hCG–LHCGR fusion protein and 
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D556H rat LHCGR under the control of the inhibin α subunit 
promoter (50).
LHβ Knockout Mice
Phenotype of Male Mice
LHβ knockout mice were generated by deleting the coding 
sequence of the Lhb gene (43). Heterozygous mice were fertile 
and homozyous male and female mice were infertile. Serum 
levels of LH were undetectable, while serum FSH levels were 
normal. Male mice had significantly smaller testes and accessory 
glands consistent with reduced levels of serum and testicular 
testosterone. Testes contained very few Leydig cells, which were 
mostly fetal and immature adult Leydig cells as indicated by 
increased levels of serum androstenedione and upregulation of 
the fetal Leydig cell marker, thrombospondin. Spermatogenesis 
in the mutant mice was arrested at the round spermatid stage, 
indicating that LH and/or testosterone are required for the last 
step in spermatogenesis. Some Sertoli cell markers (FSHR) and 
inhibin α were unchanged in the knockout mice, while others 
(anti-mullerian hormone and the inhibin β subunits) were 
upregulated, indicating that lack of LHβ caused both somatic 
and germ cell defects. Sexual differentiation and fetal gonadal 
development was normal in the knockout mice, indicating that 
pituitary LH is not required for fetal testosterone production 
and gonadal development. A similar result was seen in mice 
lacking the common alpha subunit (α-GSU) for gonadotropin 
hormones (51).
Phenotype of Female Mice
Female KO mice were also infertile with abnormal estrous cycles. 
Serum estradiol and progesterone were greatly reduced. Primary 
and secondary follicles were present in the ovary, but healthy 
antral, preovulatory, and corpora lutea (CL) were absent. Antral 
follicles contained degenerating oocytes. However, the theca cell 
layer appeared normal, indicating that the differentiation of this 
layer was independent of LH signaling. Expression of steroido-
genic enzyme genes was reduced in both sexes consistent with the 
reduction in steroid hormone levels. Treatment of the knockout 
mice with hCG rescued the phenotype in both male and female 
mice, indicating that receptor responsiveness was normal.
LHCGR Knockout Mice (LuRKO)
Two groups independently reported the development of the 
LHCGR knockout mice by deleting part of the promoter region 
and exon 1 (41) or exon 11 encoding the transmembrane and 
intracellular domain of the receptor (42). Both models showed 
a complete loss of functional receptor resulting in infertility in 
both sexes. The reproductive phenotypes described by the two 
groups were similar.
Phenotype of Male Mice
Sexual differentiation was normal, demonstrating again that, 
unlike in humans, fetal testosterone production required for 
masculinization is gonadotropin independent in mice, as pre-
viously shown with the LHβ and the common alpha subunit 
(αGSU) knockout models (43, 51). The mice were phenotypically 
normal at birth. Postnatally, the mice exhibited cryptorchidism, 
reduced testis size, poorly developed accessory sex glands, and 
micropenis. Testosterone levels were dramatically reduced while 
levels of both serum LH and FSH were increased. The testis had 
dramatically reduced Leydig cell numbers and spermatogenesis 
was arrested in the round spermatid stage (41, 42). The slightly 
elevated FSH levels in the LuRKO mice apparently stimulated 
spermatogenesis to the round spermatid stage. Further analysis 
revealed that the testicular histology of the LuRKO mice was 
similar to wild type (WT) mice until about 3 weeks of age. After 
3 weeks, the growth rate of the testis was dramatically decreased 
(52) and the interstitium lacked adult-type Leydig cells. Leydig 
cell-specific and steroidogenic enzyme genes showed similar 
level of expression in the neonatal WT and LuRKO mice but the 
LuRKO did not show the pubertal increase seen in WT mice. 
Testicular testosterone levels were similar between the genotypes 
at birth. Expression of the fetal Leydig cell marker Tsp2 was similar 
between the genotypes but the adult Leydig cell markers, Hsd3b6 
and Hsd17b3, were downregulated at postpubertal ages. Together, 
these data suggested that testosterone production by fetal Leydig 
cells and initial differentiation of the adult Leydig cell population 
are not dependent on LHCGR action. However, differentiation 
to the mature Leydig cells with steroidogenic potential requires 
LHCGR signaling.
Testosterone replacement therapy at puberty restored full 
spermatogenesis and testicular descent, but failed to restore adult-
type Leydig cells (53, 54), indicating that androgen-independent 
actions of LH are required for adult Leydig cell differentiation. 
However, the fertility of the mice could not be completely restored 
(54, 55). The subfertile phenotype was determined to be due to 
reduced epididymal sperm counts and low ejaculatory frequency. 
Additionally, inflammation in the prostate and vas deferens was 
observed (54). Interestingly, additional studies by Zhang et  al. 
(56) reveal that complete spermatogenesis with the appearance 
of elongated spermatids can be observed in the LuRKO mice 
at 12 months of age although intratesticular testosterone levels 
remained suppressed and similar to the levels in 2-month-old 
mice. This result suggested that the low level of constitutively 
produced intratesticular testosterone was sufficient for differen-
tiation of round to elongated spermatids.
Phenotype of Female Mice
Female KO mice were phenotypically normal at birth, which is 
not surprising since female sexual differentiation is independ-
ent of ovarian function and ovarian LHCGR expression begins 
after birth (57, 58). The age of vaginal opening was delayed in 
the KO mice and they did not exhibit normal estrous cyclicity. 
The uterus was atrophic with a thinning of all layers and lack of 
endometrial glands. Serum levels of estradiol and progesterone 
were suppressed but not absent (41). Estradiol and progesterone 
replacement therapy of 4-week-old KO mice for a period of 
3  weeks stimulated vaginal growth and increased uterine size 
(55). However, the number of endometrial glands remained low 
and fertility was not restored. The ovaries were greatly reduced 
in size and ovaries contained preantral and antral follicles but 
no preovulatory follicles or CL (41, 42). This indicates that both 
ovulation and the maturation of antral to preovulatory follicles 
require LH action. The requirement of LHCGR action for follicle 
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maturation beyond the antral stage was novel and was further 
investigated in the LuRKO mice (59). This study showed that pro-
gression of folliculogenesis beyond the antral stage and induction 
of ovulation could not be achieved by hCG or recombinant FSH 
in the absence of LHCGR.
Knockin Mice expressing the Constitutively 
Active Mutant D582G LHCGR (KiLHRD582G)
We have recently generated mice expressing a constitutively 
active Asp582Gly (D582G) mutant in the mouse LHCGR (44). 
The mice are heterozygous with one WT allele replaced by the 
mutant allele as seen in patients with FMPP. Expression from 
both WT and mutant alleles could be detected in the testis. This 
mutation is analogous to the most prevalent Asp578G muta-
tion in humans with FMPP. When tested in cell culture, the 
mouse D582G LHCGR showed a similar binding affinity as WT 
LHCGR. However, the basal level of cAMP was 23-fold higher 
in cells expressing the mutant receptor compared to WT. These 
levels are much higher than the three- to fourfold increase in 
basal cAMP seen with the human LHCGR (22, 60), and similar 
to that obtained with the D578H mutation found in Leydig cell 
adenomas (30).
Phenotype of Male Mice
KiLHRD582G mice exhibited precocious puberty as shown by the 
advancement of balanopreputial separation and the early detec-
tion of mouse urinary proteins in the urine by 15 days compared 
to 22 days for WT mice (44). Both are androgen-dependent events 
and indicators of puberty in mice (61, 62). Testosterone levels 
were elevated as early as 7 days of age while gonadotropin levels 
were suppressed. The high testosterone levels resulted in enlarged 
seminal vesicles and prostate but not in significantly higher body 
weights. Several of the Leydig cell-specific genes involved in the 
steroidogenic pathway, including Lhcgr were upregulated. In 
spite of the precocious puberty, no advancement in the timing 
of spermatogenesis was seen. Spermatogenesis and Sertoli cell 
development and function appeared unaffected although testis 
size was decreased in the KiLHRD582G mice presumably due to 
the suppressed FSH levels. Significantly, Leydig cell hyperplasia 
was detected as early as 7 days (Figure 1). The hyperplasia was 
patchy with a higher prevalence around the periphery of the testis. 
Precocious maturation of adult Leydig cells occurred in the mutant 
mice leading to the hyperplasia. The severity of the hyperplasia 
appeared to increase in the older animals (Figure 1). Interestingly, 
the KiLHRD582G mice became progressively infertile and were 
unable to produce litter after an average age of 5–6 months. This 
was not due to a defect in spermatogenesis as the number of total 
and motile sperm from the cauda epididymis of 6-month-old 
KiLHRD582G mice was not different from the WT mice.
Phenotype of Female Mice
Female KiLHRD582G mice exhibited precocious puberty and the 
age of vaginal opening was advanced by 2 weeks compared to 
WT mice (45). Mutant mice demonstrated irregular estrous 
cyclicity and were infertile. A temporal study from 2 to 24 weeks 
of age demonstrated elevated levels of androstenedione, testos-
terone, estradiol, and progesterone in the serum of KiLHRD582G 
FiGURe 1 | Leydig cell hyperplasia in KiLHRD582G mice. Representative 
photomicrographs of PASH stained testis sections of WT and KiLHRD582G 
from 7 days to 24 weeks of age. At least three animals per age and genotype 
were examined. The Leydig cell interstitium is marked by the dashed lines 
in sections from the 7-day-old mice. Sections of testis from two 24-week-old 
KiLHRD582G mice shows variation in the severity of the Leydig cell hyperplasia. 
Bar = 100 μm. From McGee and Narayan (44).
mice compared to WT mice. Consequently, gonadotropin levels 
were suppressed. The ovaries and uterus of the KiLHRD582G 
mice were enlarged and large cysts were apparent in the gross 
morphology of the ovaries. The ovarian histology was normal 
in the 2-week-old KiLHRD582G mice. However, degenerating fol-
licles and hemorrhagic cysts were observed starting at 3 weeks 
of age (Figure 2). Follicles did not progress beyond the preantral 
stage likely due to lack of FSH stimulation. CL were not present 
indicating anovulation. Extensive stromal cell hypertrophy 
and hyperplasia with luteinization was apparent. In 6-month-
old mice, granulosa cell tumors were evident in 50% of the 
KiLHRD582G mice. Interestingly, the anovulatory phenotype could 
FiGURe 2 | Ovarian pathology in KiLHRD582G mice. Representative 
photomicrographs of H&E stained ovary sections of WT and KiLHRD582G mice. 
At least three animals per age and genotype were examined. Higher 
magnification of the boxed areas in sections of KiLHRD582G mice at 4, 6, 12, 
and 24 weeks are shown in the last column. C, hemorrhagic cyst; GCT, 
granulosa cell tumor; AF, atretic follicle. Arrow indicates tubulostromal 
hyperplasia. Scale bars represent 100 μm. From Hai et al. (45).
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not be rescued by superovulation with pregnant mare serum 
gonadotropin (PMSG) and hCG. Although preovulatory 
follicles with oocytes could be detected in the ovaries of the 
KiLHRD582G mice, they did not rupture to form CL. This result 
suggests that neither the WT or D582G mutant LHCGR is 
able to respond to exogenous gonadotropins. LH-dependent 
induction of Gαs/cAMP is required for the activation of 
the EGF network and the ERK1/2 cascade responsible for 
oocyte maturation and cumulus expansion while LH activa-
tion of Gαq/11 and Gαs is required for ovulation (6, 16). 
Coexpression of a constitutively active hLHR (L457R) that 
was unresponsive to additional hormone stimulation, with 
the WT LHR in cell culture, caused an attenuation of the 
hCG/Gαs stimulated cAMP production by WT LHCGR (63). 
This attenuation was not due to a decrease in the cell surface 
expression of the WT receptor, but due to the activation 
of phosphodiesterase 4D3 resulting in decreased levels of 
cAMP. Perhaps a similar mechanism occurs in  vivo in the 
granulosa cells of the KiLHRD582G mice to inhibit ovulation. 
The body weights of KiLHRD582G mice were higher than that 
of WT mice. However, there were no changes in body fat 
composition or insulin resistance as seen in experimentally 
induced hyperandrogenic rodent models of polycystic ovar-
ian syndrome (PCOS).
LHβ Overexpressing Transgenic Mice
Transgenic mice expressing a chimeric protein (bLHβ-CTP) con-
sisting of the bovine LHβ subunit fused in frame to the C-terminal 
peptide of hCGβ subunit driven by the pituitary-specific bovine 
glycoprotein α-subunit (α-GSU) promoter was first reported by 
Risma et al. (46). The addition of the CTP increased the circulatory 
half-life of LH resulting in constitutive high levels (5- to 10-fold) 
in the female but not male mice. Preliminary observations with 
the male mice showed reduced fertility and smaller testis in spite 
of normal hormone levels and the mice were not characterized 
further. Female LHβCTP mice presented with precocious puberty, 
elevated levels of testosterone, and estradiol and infertility due to 
anovulation (64). The predominant ovarian phenotype was the 
presence of hemorrhagic cysts with widespread luteinization of 
the interstitial tissue. Accelerated depletion of primordial follicles 
was also observed (65). Although anovulation could be reversed by 
treatment with exogenous gonadotropins, pregnancy could not be 
maintained due to defects in uterine receptivity and mid-gestation 
pregnancy failure (66). Additional ovarian defects included granu-
losa cell tumors by 5 months of age only in the genetic background 
of CF-1 mice (67). In a hybrid background, the phenotype 
resembled the luteoma of pregnancy and it was shown that three 
genes likely control the different phenotypes (67). In addition to 
the ovarian tumors, the LHβCTP mice also developed mammary 
gland tumors (68). An interesting non-reproductive phenotype 
resulting from the elevated LH in the LHβCTP mice is adrenal 
hyperplasia and induction of LHCGR expression and activity in the 
adrenal gland. As a result, corticosterone production is stimulated 
(69). This phenotype was dependent on the dysfunctional ovaries 
of the transgenic mice as gonadectomy abolished the adrenocorti-
cal hyperfunction. LHβCTP mice also have elevated levels of 
prolactin caused by the enhanced estrogen synthesis (69). It has 
been suggested that prolactin synergizes with LH in the induc-
tion of LHCGR expression in the adrenal glands. Additionally, 
LHβCTP female mice are obese (70). Obesity was associated with 
hyperphagia, increased intra-abdominal fat, increased levels of 
serum leptin and insulin, and reduced thermogenic activity of 
brown adipose tissue. The elevated androgens and corticosterone 
most likely contribute to the obesity seen in the LHβCTP females 
as ovariectomy normalized corticosterone levels and reversed the 
obesity and hyperphagia (70). Transgenic females also developed 
renal abnormalities, including enlarged bladders, dilated ureters, 
and hydronephrosis presumably due to the elevated steroids (46).
hCG Overexpressing Mice
Additional models of enhanced LH/hCG action were indepen-
dently developed by two groups. Supraphysiological levels of hCG 
were expressed using the human ubiquitin C promoter or the mouse 
metallothionein-1 (MT-1) promoter (47–49). Transgenic mice 
expressing only the hCGβ subunit or both the common α subunit 
and hCGβ from multiple tissues were examined in both sexes.
Phenotype of Male Mice
In male mice expressing only the hCGβ subunit (hCGβ+) under 
the human ubiquitin C promoter, circulating levels of dimeric 
hCG were detected, indicating that the hCGβ subunit associated 
with the endogenously produced α subunit in the pituitary (48). 
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However, dimeric hCG levels were only 3-4 fold higher than WT 
mice because the amount of endogenous α−GSU produced by the 
pituitary is rate-limiting. These mice were fertile and presented 
with only a mild reproductive phenotype of smaller testes (48). 
By contrast, mice expressing the hCGβ subunit under the mouse 
MT-1 promoter were infertile although hCG dimer could not be 
detected in the serum of these mice and the testes were morpho-
logically and physiologically normal (49). This was surprising as 
individual subunits of hCG are devoid of activity (71).
Mice expressing both subunits (hCGαβ+) under the control 
of the ubiquitin C promoter produced extremely high levels of 
dimeric hCG with about 2000-fold increase in circulating LH/
hCG bioactivity in male mice (48). Serum and testicular testos-
terone and progesterone were elevated in spite of down regulation 
of receptor expression. Male mice were infertile and vaginal plugs 
were not observed when mice were mated with superovulated 
females in spite of motile and morphologically normal sperm in 
the cauda epididymis. Adult mice at 2–6 months of age showed 
smaller testes with normal tubular structure. However, progres-
sive degenerative changes in the seminiferous tubules were 
observed. Mice developed focal Leydig cell hyperplasia/hyper-
trophy but not adenomas. Subsequent studies in prepubertal mice 
showed Leydig cell adenomas that were of fetal Leydig cell origin 
and disappeared at puberty (72). No sign of precocious puberty 
was observed in these young mice in spite of elevated levels of 
testosterone. The seminal vesicle and prostate were enlarged. The 
distention and sperm accumulation in the distal vas deferens 
as well as the dilated urinary bladder and ureters and enlarged 
kidneys pointed to a functional uretheral obstruction caused by 
the overproduction of secretory fluids or impaired emptying of 
the accessory glands. This may be a likely cause of infertility in 
these mice. Aggressive behavior of the males toward the females 
during mating may also contribute to the infertile phenotype.
Matzuk et al. used the MT-1 promoter to generate transgenic 
mice expressing low and high levels of the dimeric hCG (49). 
Males with low levels of heterodimer expression showed pro-
gressive infertility of unknown etiology. Adult males with high 
expression levels had similar reproductive defects as described 
above, including reduced testis size, Leydig cell hyperplasia, 
enlarged fluid-filled seminal vesicles, elevated testosterone levels, 
and infertility. Males were very aggressive toward both transgenic 
and non-transgenic males or females.
Phenotype of Female Mice
In contrast to male mice, female transgenic hCGβ+ mice using 
the ubiquitin C promoter associated with the endogenously 
expressed mouse α-subunit to produce a 40-fold increase in 
bioactive LH/hCG compared to WT females (47). Although 
female hCGαβ+ mice expressing both subunits as transgenes 
produced a 2000-fold elevation in bioactive LH/hCG, the 
phenotype of the hCGβ+ and hCGαβ+ mice were similar. Mice 
presented with precocious puberty, disrupted estrous cycles, 
and infertility. Adult mice were obese due to abdominal fat 
accumulation. Transiently elevated estradiol and persistent 
elevation of testosterone and progesterone were observed in 
the transgenic mice. The ovaries were significantly enlarged 
with massive luteinization, resembling luteomas, which may 
explain the transient increase in estradiol. Hemorrhagic cysts 
and CL were present. Females also developed macroprolacti-
nomas and mammary gland tumors at 9–12  months of age. 
Serum prolactin was greatly elevated and may help maintain the 
ovarian luteinization and progesterone production. Metastasis 
of the mammary tumors to the liver, spleen, and lung was seen 
in about 47% of the mice. The mammary gland and pituitary 
tumors were dependent of ovarian function and ovariectomy 
prevented their development even when hCG levels were high. 
Subsequent studies (73) showed that the hCGαβ+ mice with the 
2000-fold elevation in bioactive LH/hCG develop teratomas.
Mice overexpressing only the hCGβ subunit under the MT-1 
promoter were infertile although heterodimer could not be detected 
in the serum (49). These mice also had ovarian defects, including 
block in folliculogenesis and cysts. Mice with low levels of hCG 
dimer became progressively infertile. Mice expressing high levels 
of hCG dimer had elevated estradiol levels and developed enlarged 
cystic and hemorrhagic ovaries with stromal cell proliferation and 
enlarged thecal cell layers. Degenerating kidneys were also evident. 
These mice did not develop mammary gland or pituitary tumors.
Yoked Hormone Receptor and Rat D556H 
LHCGR Transgenic Mice
Transgenic mice expressing a yoked hormone receptor (YHR+) 
genetically engineered by covalently linking hCG to LHCGR 
was generated to create a model for constitutively active LHCGR 
mutations. In cell culture, YHR exhibited an increase in the 
basal level of both cAMP and inositol phosphate similar to that 
seen with constitutively active mutants (50, 74). The transgene 
was expressed under the control of the gonadal-specific inhibin 
α-subunit promoter and male mice were fertile (75). Serum and 
testicular testosterone levels were elevated in YHR+ mice at pre-
pubertal ages of 3 and 5 weeks, but not at 8 and 12 weeks of age. 
Consistent with the increased testosterone was the increase in 
seminal vesicle weights. However, there was no evidence of preco-
cious puberty. Serum levels of LH and FSH were decreased due to 
elevated testosterone. Testis size was decreased at all ages in YHR+ 
mice and histological analysis showed a significant decrease in 
the cross-sectional area of the tubules. Spermatogenesis was not 
initiated earlier and Leydig cell hyperplasia, as seen in patients 
with constitutively active LHCGR, was also not observed. Further 
characterization of the male phenotype showed a reduction in 
the number of Leydig cells in YHR+ mice accompanied by a 
reduction in the expression of several Leydig cell specific genes 
(76). The difference in the phenotype of the YHR+ mice from 
humans with activating LHCGR mutations is likely because the 
inhibin α-subunit promoter did not faithfully mimic the spatial 
and temporal expression of LHCGR.
Female YHR+ mice exhibited precocious puberty and were 
subfertile. Increased levels of estradiol and progesterone were 
observed at 5  weeks of age. However, the hormonal changes 
were no longer apparent in adult mice. Increased folliculogenesis 
and CL were observed in 5-week-old mice and interstitial cell 
hypertrophy, degenerating follicles, and follicular cysts were 
observed in adult mice.
Transgenic mice expressing the rat D556H LHCGR under the 
control of the inhibin α-subunit promoter was also generated 
TABLe 1 | Summary of genetic models for the study of LHCGR function.
Gene (mutation/
mouse model)
Major human phenotypes Major mouse phenotypes Reference
A. COMPARiSON OF HUMAN AND MOUSe PHeNOTYPeS FOR iNACTivATiNG AND ACTivATiNG MUTATiONS iN LH AND LHCGR
LHB (inactivating/
knockout)
Male: infertility, delayed puberty, hypogonadism, Leydig cell 
hypoplasia, spermatogenic arrest, normal sexual differentiation
Male: infertility, hypogonadism, Leydig cell hypoplasia, 
spermatogenesis arrested at round spermatid stage, normal 
sexual differentiation
(43)
Female: normal pubertal development, normal uterus, 
folliculogenesis blocked at antral stage, secondary 
amenorrhea, infertility
Female: hypogonadal, folliculogenesis blocked at antral stage, 
hypoplastic uterus, infertility
LHCGR (inactivating/
knockout)
Male: micropenis, hypospadia, pseudohermaphroditism, 
Leydig cell hypoplasia, germ cell defects
Male: infertility, Leydig cell hypoplasia, underdeveloped sex 
organs, spermatogenesis arrested at round spermatid stage, 
normal sexual differentiation
(41, 42)
Female: normal pubertal development, amenorrhea, 
folliculogenesis blocked at antral stage, infertility
Female: delayed puberty, underdeveloped accessory glands, 
follicles arrested at antral stage, infertility
LHCGR (activating/
knockin)
Male: precocious puberty, Leydig cell hyperplasia, 
high testosterone
Male: precocious puberty, Leydig cell hyperplasia, high 
testosterone, progressive infertility
(44, 45)
Female: normal Female: precocious puberty, cystic hemorrhagic ovaries 
with stromal cell hyperplasia with luteinization, granulosa cell 
tumors, infertility
Construct Major phenotypes Reference
B. TRANSGeNiC MOUSe MODeLS OF eNHANCeD LH/hCG ACTiON
α-GSU promoter/
bLHβ-CTP
Males: subfertility, smaller testis (46, 66, 67)
Females: precocious puberty, infertility, polycystic ovaries, 
stromal cell luteinization, granulosa cell tumors, mammary 
gland tumors, hydronephrosis
Ubiquitin C promoter/
hCGβ
Males: no phenotype (47, 48)
Females: precocious puberty, infertility, luteinized cystic 
ovaries, prolactinomas, mammary gland tumors
Ubiquitin C promoter/
hCGαβ
Males: infertility, adult Leydig cell hyperplasia, fetal Leydig cell 
adenomas, urethral obstruction, and kidney defects
(48, 73)
Females: infertility, ovarian teratomas
MT-1 promoter/hCGβ Males: infertility (49)
Females: infertility, cystic, and hemorrhagic ovaries
MT-1 promoter/hCGαβ Males: infertility, Leydig cell hyperplasia (49)
Females: infertility, cystic, and hemorrhagic ovaries, 
degenerating kidneys
Inhibin α-subunit 
promoter/YHR
Males: fertile, elevated testosterone with smaller testis, and 
Leydig cell hypoplasia
(75)
Females: subfertile, precocious puberty, interstitial cell 
hypertrophy
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(50). This mutation corresponds to the somatic D578H mutation 
found in Leydig cell adenomas (30–32). Unfortunately, male and 
female mice expressing the transgene were infertile which pre-
vented their further characterization. Preliminary analysis of two 
infertile founder male mice did not show testicular adenomas.
Comparison of the Mouse Models with 
Human Reproductive Pathologies of 
LHCGR Function
inactivating Mutations and Knockout Models
The mouse models of inactivation of LHCGR function have veri-
fied existing knowledge, but more importantly have provided new 
information on the function of LH. Although the homozygous 
inactivating mutations in the LHB gene result in single amino acid, 
changes they cause result complete loss of bioactivity similar to 
the deletion of the Lhb gene in the mouse. The phenotype of the 
homozygous LHβ knockout male and female mice closely mimics 
that of humans with the inactivating LHβ mutations (Table  1). 
In males, sexual differentiation is normal in humans and mice. 
However, in humans, testosterone required for masculinization 
in utero is dependent on placental hCG stimulating LHCGR while 
in mice it is independent of LH action. LH is critical postnatally and 
both humans and mice show hypogonadism, low testosterone levels, 
arrest of spermatogenesis, Leydig cell hypoplasia, and infertility.
Female LHβ knockout mice displayed several characteristics 
similar to the single female patient with LHβ inactivating muta-
tion identified thus far. Folliculogenesis was arrested at the antral 
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stage resulting in infertility. Surprisingly, this patient had normal 
puberty, with normal sized ovaries and breast and uterine devel-
opment. Presumably, the low level of estradiol was sufficient for 
normal breast and uterine development (35).
Inactivating mutations in LHCGR in human males have a 
more severe phenotype, resulting from abnormal sexual dif-
ferentiation, that those in LHβ emphasizing the importance of 
LHCGR signaling in sexual development and postnatal pubertal 
development. By contrast, the LuRKO mouse demonstrates that 
LHCGR signaling is not essential for mouse sexual differentia-
tion, highlighting a major species difference. LHCGR activation 
is, however, important for postnatal development in both species. 
The phenotypes of the LHβ and LHCGR knockout male mice are 
very similar. Spermatogenic arrest at the round spermatid stage 
in both models indicates that FSH alone is not sufficient for full 
spermatogenesis and that testosterone produced by LH signaling 
is required for postmeiotic germ cell maturation. A novel observa-
tion that resulted from studies on the LHCGR knockout mice was 
that at 12 months of age, qualitatively complete spermatogenesis 
was possible in the absence of LH stimulated high testosterone 
production (56). This process, however, requires a long priming 
period. From a clinical standpoint, this finding may explain why 
men treated with testosterone for contraceptive purposes are not 
azoospermic (56).
Women with inactivating LHCGR and LHβ mutations have 
normal pubertal development, indicating that LH signaling is not 
essential for puberty in women. This process is more dependent 
on FSH signaling as demonstrated by lack of pubertal develop-
ment in women with inactivating mutations in the FSHβ or 
FSHR (77). LH signaling is, however, required in the mouse where 
absence of LHCGR delays pubertal development (Table 1). There 
is a remarkable similarity in the ovarian phenotype of women 
with inactivating LHβ and LHCGR mutations, LHβ knockout 
and LuRKO mice showing a block in folliculogenesis at the antral 
stage. The studies from these mouse models clearly showed for 
the first time that, in addition to its well-known role in ovulation, 
LH is also required for the final stage of follicular maturation 
before ovulation. Studies with the LuRKO mice (59) also clarified 
that ovulation could not be induced by FSH in the absence of 
functional LHCGR as has been previously suggested (78, 79).
Activating Mutations and Knockin Models
The most common mutation in FMPP is the D578G mutation 
in transmembrane helix 6. In the mouse model (KiLHRD582G) 
generated in our laboratory, the corresponding D582G mutation 
was introduced into the WT Lhcgr gene (44). The male mouse is 
a good phenocopy of men with constitutively activating LHCGR 
mutations as shown by the development of precocious puberty, 
Leydig cell hyperplasia and high testosterone (Table 1). A major 
difference between the mouse model and FMPP patients is that 
spermatogenesis is not advanced in the KiLHRD582G mouse. 
Presumably, the seminiferous cycle of 35 days is at a minimum 
in mice and cannot be shortened further even with premature 
testosterone production. Furthermore, spermatogenic develop-
ment requires the expression of the androgen receptor in Sertoli 
cells and significant levels are not detected till around postnatal 
day 15 in mice (80). It has been demonstrated that premature 
expression of the androgen receptor in Sertoli cells can acceler-
ate spermatogenic development (80). Two new findings form the 
mouse model, not previously reported or confirmed in FMPP 
cases, are that the hyperplasia is not uniform throughout the 
testis and that it results from the precocious development of 
adult Leydig cells. The progressive infertility and hyperplasia 
seen in the KiLHRD582G mice suggest that FMPP patients may 
be susceptible to infertility and perhaps tumor development 
later in life. There is only one report of a FMPP patient with the 
D578G mutation who was diagnosed with nodular Leydig cell 
hyperplasia (81), primarily due to lack of long-term follow-up of 
FMPP patients past puberty.
The phenotype of female KiLHRD582G mice (45) is distinctly 
different from women with activating mutations who are normal 
(82–84). Mice undergo precocious puberty and are infertile with 
significant ovarian pathology of hemorrhagic cysts, stromal 
cell hyperplasia, and granulosa cell tumors. The reason for this 
discrepancy is unclear. The low level of LHCGR expression in 
prepubertal girls, the requirement for the activation of both 
LHCGR and FSHR for puberty, and less efficient androgen syn-
thesis in theca cells compared to Leydig cells (4, 82). A higher 
magnitude of LHCGR activation may be required for develop-
ment of ovarian pathology. In this context, the mouse LHCGR 
has a higher level of constitutive activation than the human 
receptor and the phenotype of the female KiLHRD582G mice is 
similar to transgenic models of LH and hCG overexpression. A 
novel finding from the study of KiLHRD582G mice is the dominant 
negative effect of the mutant receptor on the function of the WT 
receptor. The lack of rescue of the anovulatory phenotype by 
the administration of PMSG and hCG indicated that D582G 
LHCGR inhibits signaling of the WT receptor and is the first 
report of such an effect in vivo.
In general, the knockout and knockin mouse models are 
close phenocopies of the human disorders; however, species 
differences in LHCGR function clearly exist. Although these 
differences provide useful knowledge on LHCGR physiology, 
they should be considered when the mice are used as models of 
human diseases.
Transgenic Models of enhanced LH/hCG Action
Activating mutations in LH or hCG have not been identified. 
However, there are physiological and pathological states when 
these hormone levels are elevated. hCG is produced in high 
amounts in the first trimester of pregnancy and in gestational 
trophoblastic disease (1). In men and women, hCGβ, hyper-
glycosylated hCGβ, and occasionally hCG dimer are secreted 
from a variety of tumors (1). Gonadotroph adenomas induce 
high gonadotropin levels and hypersecretion of LH is observed 
in pathological conditions such as PCOS. Chronic elevation of 
gonadotropins occurs in menopause and this is proposed as risk 
factor for ovarian cancer (85).
A comparison of the phenotypes of the overexpressing LH/
hCG mice is shown in Table  1. The LHβ-CTP model was the 
first overexpressing model described. Hormone levels were not 
elevated in male mice because the α-GSU promoter is inefficient 
in the male. Overexpression of dimer hCG driven by either the 
ubiquitin C or MT promoter resulted in similar male phenotypes 
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of infertility and Leydig cell hyperplasia with high testosterone 
levels. Aggressive behavior of the males toward the females was 
observed in both hCG models and this may contribute in part 
to the infertile phenotype. The infertility in the ubiquitin C 
promoter-driven hCG mice was not due to defects in sperm but 
possibly due to the urethral obstruction (48).
The pathological changes seen in the female LHβ-CTP and 
hCG overexpressing mice were similar with precocious puberty 
and infertility. Significant pathology was seen in all models, with 
cystic, hemorrhagic, and luteinized ovaries. Granulosa cell tumors 
were seen in the LHβ-CTP mice, but ubiquitin C promoter-hCG 
mice had ovarian luteomas and teratomas and no tumors were 
found in the MT-hCG mice. Both LHβ-CTP and ubiquitin C 
promoter-hCG mice develop mammary gland tumors, but the 
latter also develop prolactinomas in older mice. This indicates that 
chronic high levels of gonadotropins promote tumor formation 
in gonadal and non-gonadal tissues. The pituitary and mammary 
gland tumors are secondary effects of aberrant gonadal function. 
The inhibin α-subunit promoter-YHR mice did not exhibit the 
robust changes seen in the overexpressing mice in either males 
or females.
The LH/hCG overexpressing models and the inhibin α-subunit 
promoter-YHR mice were expected to mimic the activating 
LHCGR mutations by precocious activation of the receptor. 
Comparison of the male KiLHRD582G mice with the transgenic 
mouse models of LH/hCG overexpression showed similar phe-
notypes of Leydig cell hyperplasia and high testosterone. Similar 
to the ubiquitin C promoter-hCG mice, the progressive infertility 
in the KiLHRD582G mice was not due to sperm defects. However, 
there were distinct differences as well. The overexpressing models 
did not exhibit precocious puberty and Leydig cell adenomas in 
the ubiquitin promoter-hCG mice were of fetal origin rather than 
from adult Leydig cells as seen in the KiLHRD582G mice. The inhi-
bin α-subunit promoter-YHR mice did not exhibit phenotypes 
similar to either the KiLHRD582G mice or LH/hCG overexpressing 
mice except for the increase in testosterone. Presumably, the 
promoter used was regulated differently from the endogenous 
LHCGR.
The reproductive (precocious puberty, infertility) and ovar-
ian phenotypes (cystic, hemorrhagic ovaries, interstitial cell 
hypertrophy with luteinization, granulosa cell tumors) of the 
KiLHRD582G mice are similar to the LH/hCG overexpressing 
mice. The luteomas, teratomas (47), and enlarged thecal cell 
layer are specific to the hCG overexpressing mice (49, 73). 
The extra-gonadal phenotypes of pituitary and mammary 
gland tumors are not also seen in the KiLHRD582G mice. The 
obese phenotype seen in the LHβ-CTP and ubiquitin-hCG 
overexpressing mice is not evident in the KiLHRD582G mice. In 
contrast to the KiLHRD582G mice, the anovulatory phenotype of 
the LHβ-CTP could be rescued by exogenous gonadotropins 
(66), further confirming an inhibition of WT LHCGR func-
tion in the KiLHRD582G mice. The differences in the phenotypes 
between the overexpressing models and KiLHRD582G mice, 
particularly the extra-gonadal phenotypes, are likely due to 
the high levels of LH/hCG secreted by transgenes that were 
expressed ubiquitously under the control of promoters that do 
not mimic the spatial or temporal expression of LHCGR. Some 
of the differences between the three overexpressing models 
may be the result of different levels of hormone production, 
different promoters, and genetic background. However, the 
remarkable number of similarities between the models empha-
sizes the importance of LH/LHCGR action on reproductive 
physiology and pathophysiology.
Future Perspectives
Mouse models are now available that can mimic the genetic 
alterations in LH and LHCGR and physiological and pathologi-
cal states of hormone excess. These models have reinforced the 
well-established roles of LH and LHCGR but have also uncovered 
novel functions. The KiLHRD582G mice can be used to investigate 
the long-term reproductive and non-reproductive abnormalities 
that result from constitutive LHCGR activity, particularly the 
mechanism of the progressive infertility. This information will 
be useful in predicting the long-term health of FMPP patients. 
This mouse model will be valuable to test new therapeutic agents 
that can block constitutive activity and to further determine the 
in vivo mechanism of the dominant negative effect of the mutant 
receptor on WT receptor function. Based on the phenotypic 
changes seen in the models of enhanced LH/hCG action, it 
appears that female physiology is more sensitive to changes in 
LH-mediated signaling. In particular, these models can be used 
to better understand the signaling mechanisms important in the 
development of ovarian and extra-gonadal tumors and under-
stand the role of LH in obesity and related metabolic changes. 
The models can be helpful in sorting out the controversies and 
conflicting data regarding the extra-gonadal actions of LHCGR. 
In general, all the described models are amenable to large-scale 
gene expression profiling to better understand LHCGR signaling 
mechanisms.
An area that has not been explored extensively is the neuro-
logical changes associated with LHCGR signaling. Testosterone 
is important in brain development and sexual differentiation. 
Behavioral studies have shown that FMPP patients are suscep-
tible to attention deficit hyperactivity disorder and a higher 
rate of anxiety disorder (86). The KiLHRD582G mice are an ideal 
animal model to assess cognitive and behavioral changes associ-
ated with FMPP. There is also increasing evidence that elevated 
levels of LH can exacerbate age-related cognitive decline in 
Alzheimer’s disease (87, 88). LHβ-CTP mice exhibit cognitive 
deficits (89). Considering that functional LHCGR is expressed 
in the brain (90), it will be of interest to determine if cognitive 
and behavioral changes are due to direct LHCGR signaling 
in the brain or indirectly due to its activity in gonads. These 
mechanisms and the contributions of direct vs. indirect effects 
on the brain can be teased out with the mouse models. Clearly, 
these mouse models have the potential to uncover novel aspects 
of LHCGR signaling.
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